Blog

Uncategorized

Search

Categories

Shortlisted for a Pharma Industry Award

Shortlisted for a Pharma Industry Award

We are thrilled that our Regulatory Team was shortlisted for a Pharma Industry Awards -Pharma Contract Services Company of the Year 2024. Our nomination is for their excellent work on implementing a client Regulatory Information Management (RIM) System.

read more
World Drug Safety Congress, Europe

World Drug Safety Congress, Europe

Our Head of PV is attending the World Drug Safety Congress during 9-10th October in Amsterdam this year. This is Europe's Most Exciting Drug Safety and PV event and with over 90+ exhibitors, 300+ speakers and 1,500 PV experts in attendance, it promises to be a truly...

read more
CPHI Milan 2024

CPHI Milan 2024

On Oct 8-10th CPhI Milan 2024 will open its doors to over 60, 000 people.  This year, our founder and CEO; Gemma Robinson and Senior Project Manager; Janet Fitzgerald will be in attendance. Pharma professionals from all around the world will converge in Milan for the...

read more
PV Audit Strategy and Risk Assessment

PV Audit Strategy and Risk Assessment

From our experience, companies are falling short of their pharmacovigilance obligations with regards to strategic, tactical and operational level PV audit planning. This can lead to areas of non-compliance, risks to patient safety and inspection findings. Outlined...

read more
BioPharmaChem Impact 24 Conference

BioPharmaChem Impact 24 Conference

We were delighted to attend the 1st ever BioPharmaChem Impact 24 Conference which took place yesterday May 23rd in the beautiful surroundings of Fota Island Resort, Cork.

read more
Why its better to trust Acorn Regulatory to manage your entire product lifecycle?

Why its better to trust Acorn Regulatory to manage your entire product lifecycle?

Discover the challenges and advantages of outsourcing various pharmaceutical services to multiple providers versus a single service provider. From managing the product lifecycle to ensuring regulatory compliance and communication between teams, find out how a cohesive approach can streamline processes and reduce costs. At Acorn Regulatory, we prioritise your product’s success with our global expertise and commitment to excellence.

read more
EMA Addresses Stakeholder Queries

EMA Addresses Stakeholder Queries

The EMA has issued Questions and Answers to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use.

read more
MHRA Updated NIMAR Guidance to reflect Windsor Framework

MHRA Updated NIMAR Guidance to reflect Windsor Framework

Get up-to-date information about the Northern Ireland MHRA Authorised Route (NIMAR). Check out the recent MHRA Windsor Framework-aligned guidance changes to ensure the legal supply of POMs in the UK and EU. Discover how the Windsor framework will allow ‘PL GB’ packs to be sold in Northern Ireland in January 2025.

read more
Labelling and packaging of human-use drugs after Windsor Framework agreement

Labelling and packaging of human-use drugs after Windsor Framework agreement

“MHRA updates guidance for UK medicinal product labeling and packaging. Effective January 1, 2025:EU/UK joint packs not allowed in the supply chain.Medicines in the UK (including Northern Ireland) to be authorized separately by MHRA.EU Falsified Medicines Directive no longer applies; ‘UK only’ labeling required.MAHs must submit ‘UK only’ statement by December 31, 2024, with a 6-month over-sticker transition until June 30, 2025. Brought to you by Acorn Regulatory.”

read more
Choosing an RMS

Choosing an RMS

Choosing the right Reference Member State (RMS) for your EU procedure can be difficult, Here is some advice to consider, helping you make the choice for your company.

read more
Marketing Authorisation Holder Responsibilities

Marketing Authorisation Holder Responsibilities

Acorn Regulatory has worked with a number of MAHs including ‘virtual MAH’s’ to help them understand their responsibilities and develop a QMS suitable for their needs and to support them with each of these responsibilities. MA Holding entities are subject to Market Compliance Inspections by any Health Authority, in any EU country where they hold an MA. The HPRA carry out multiple MAH Market compliance inspections each year.

read more
PRRC: Person Responsible for Regulatory Compliance

PRRC: Person Responsible for Regulatory Compliance

This revised article concentrates on the role of the Person Responsible for Regulatory Compliance (PRRC). The role of QP is a familiar one for those working in the Pharma sector, but this is the first time in European Medical Devices legislation that a person is...

read more

Strategy

Subscribe to Our Newsletter

Sign up for our newsletter today and stay informed on the latest regulatory updates and industry insights.